HOYA CORPORATION (JP:7741)
:7741
Top Page
HOYA
(7741)
Select Model
Select Model
Rating:80Outperform
Price Target:
¥33,840.00
▲(14.75% Upside)
Action:ReiteratedDate:02/01/26
The score is primarily driven by strong financial performance (high profitability, very low leverage, and solid cash generation) and supportive technical momentum (price above key moving averages with positive MACD). These strengths are tempered by a relatively expensive valuation (high P/E and low dividend yield).
Positive Factors
Balance sheet strength
Very low leverage and a large equity base materially reduce financial risk and preserve flexibility. Over the next 2–6 months this supports continued investment, opportunistic M&A or shareholder returns without stressing liquidity, and cushions the business through cyclical troughs.
Negative Factors
Slowing revenue growth
A more mature growth profile with modest top-line expansion constrains earnings leverage and limits organic upside. Over 2–6 months this raises reliance on margin expansion, share buybacks or M&A to drive EPS growth and makes achieving higher growth targets more challenging.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and a large equity base materially reduce financial risk and preserve flexibility. Over the next 2–6 months this supports continued investment, opportunistic M&A or shareholder returns without stressing liquidity, and cushions the business through cyclical troughs.
Read all positive factors
HOYA (7741) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.96T
Dividend Yield1.01%
Average Volume (3M)1.07M
Price to Earnings (P/E)21.9
Beta (1Y)0.82
Revenue Growth8.83%
EPS Growth8.63%
CountryJP
Employees35,702
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)N/A
Shares Outstanding338,414,300
10 Day Avg. Volume1,057,600
30 Day Avg. Volume1,072,613
Financial Highlights & Ratios
PEG Ratio2.25
Price to Book (P/B)5.99
Price to Sales (P/S)6.73
P/FCF Ratio31.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥30,017.46Price Target Upside1.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HOYA Business Overview & Revenue Model
Company Description
HOYA Corporation operates as a med-tech company, and a supplier of high-tech and medical products worldwide. The company offers life care products, including eyeglass and contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgica...
How the Company Makes Money
HOYA makes money primarily by manufacturing and selling products across several business lines. A major revenue stream is its vision care business, where it sells prescription eyeglass lenses (and associated lens options/coatings) through optical ...
HOYA Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 916.38B | 866.03B | 762.61B | 723.58B | 661.47B | 547.92B |
| Gross Profit | 731.05B | 693.58B | 606.30B | 567.05B | 511.05B | 424.21B |
| EBITDA | 373.64B | 309.48B | 284.45B | 266.20B | 254.48B | 196.57B |
| Net Income | 250.40B | 202.10B | 181.38B | 168.64B | 164.51B | 125.45B |
Balance Sheet | ||||||
| Total Assets | 1.31T | 1.23T | 1.20T | 1.03T | 992.84B | 853.29B |
| Cash, Cash Equivalents and Short-Term Investments | 580.58B | 533.97B | 525.16B | 405.89B | 419.40B | 334.90B |
| Total Debt | 41.44B | 37.28B | 29.24B | 24.58B | 21.60B | 20.75B |
| Total Liabilities | 264.22B | 262.65B | 241.36B | 213.72B | 203.78B | 180.88B |
| Stockholders Equity | 1.03T | 974.02B | 967.76B | 818.32B | 803.85B | 688.00B |
Cash Flow | ||||||
| Free Cash Flow | 197.01B | 187.19B | 181.73B | 168.36B | 161.18B | 120.57B |
| Operating Cash Flow | 251.61B | 235.11B | 222.80B | 201.83B | 190.06B | 151.81B |
| Investing Cash Flow | -7.71B | -35.82B | -35.81B | -39.93B | -29.13B | -29.79B |
| Financing Cash Flow | -247.38B | -187.72B | -110.89B | -202.16B | -106.89B | -115.67B |
HOYA Technical Analysis
Positive
29490.00
Price Trends
27551.06
Positive
25770.37
Positive
22833.71
Positive
Market Momentum
361.25
Negative
64.66
Neutral
84.72
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7741, the sentiment is Positive. The current price of 29490 is above the 20-day moving average (MA) of 27807.15, above the 50-day MA of 27551.06, and above the 200-day MA of 22833.71, indicating a bullish trend. The MACD of 361.25 indicates Negative momentum. The RSI at 64.66 is Neutral, neither overbought nor oversold. The STOCH value of 84.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7741.
HOYA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥9.96T | 21.89 | 25.14% | 1.01% | 8.83% | 8.63% | |
74 Outperform | ¥130.86B | 9.26 | 7.81% | 1.78% | 3.17% | 7.07% | |
73 Outperform | ¥3.16T | 25.64 | 8.98% | 1.22% | 7.68% | 10.08% | |
68 Neutral | ¥937.39B | 24.33 | 11.64% | 0.82% | 13.53% | -7.39% | |
65 Neutral | ¥125.34B | 16.09 | 27.95% | 1.97% | 17.13% | 78.33% | |
59 Neutral | ¥1.73T | 38.56 | 11.34% | 1.01% | 0.42% | 34.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7741
HOYA
29,490.00
14,462.84
96.24%
JP:4543
Terumo
2,139.00
-501.88
-19.00%
JP:7747
Asahi Intecc Co
3,533.00
1,382.61
64.30%
JP:3046
JINS HOLDINGS
5,370.00
-3,287.25
-37.97%
JP:7780
Menicon Co
1,720.00
560.51
48.34%
JP:7733
Olympus
1,568.50
-179.54
-10.27%
HOYA Corporate Events
Hoya Weighs Lowering Investment Unit to Broaden Shareholder Base
Apr 10, 2026
Hoya Corporation has outlined its stance on potentially lowering its investment unit size as part of an effort to broaden its investor base and help invigorate the stock market. The company acknowledges that a lower minimum investment could make i...
Hoya Advances Aggressive Share Buyback as March Repurchases Near ¥36 Billion
Apr 1, 2026
Hoya Corporation has reported progress on its ongoing share buyback program authorized by its board in January 2026, executing market purchases of common stock on the Tokyo Stock Exchange. Between March 1 and March 31, the company repurchased 1,29...
HOYA Delays Spin-Off Date for Japanese Endoscope Business to August 2026
Mar 26, 2026
HOYA Corporation has postponed the planned spin-off of its Japanese endoscope business, which is to be transferred via a simplified absorption-type company split to its wholly owned subsidiary PENTAX Medical Corporation. The effective date, initia...
Hoya Corrects Notice on Intervention in Shareholder Derivative Suit
Mar 2, 2026
Hoya Corporation has issued a corrective notice regarding its previously announced intervention in a shareholder derivative lawsuit involving seven current and former directors and executives. The company clarified that its decision to support the...
Hoya Steps Into Shareholder Lawsuit to Support Current and Former Directors
Mar 2, 2026
Hoya Corporation has decided to intervene in a shareholder derivative lawsuit to support seven current and former directors, including its current president and CEO, after a board review concluded they bear no liability for alleged breaches under ...
Hoya Reports Progress on ¥100 Billion Share Buyback Program
Mar 2, 2026
Hoya Corporation has disclosed the latest progress of its ongoing share buyback program authorized by its board on January 30, 2026, under which it is allowed to repurchase up to 5 million shares for a maximum of ¥100 billion through mid-July...
HOYA Faces Shareholder Derivative Suit Over 2016 Share Buyback
Feb 24, 2026
HOYA has disclosed that it was notified of a shareholder derivative lawsuit filed in the Tokyo District Court against seven current and former directors and executive officers. The suit, brought by an individual shareholder, seeks ¥23,624 mil...
HOYA Delivers Strong Q3 Earnings and Lifts Full-Year Profit Outlook
Jan 30, 2026
HOYA reported a strong performance for the three months ended December 31, 2025, with revenue rising 10.8% year-on-year to ¥244.7 billion and profit before tax surging 69.9% to ¥110.8 billion, lifting the profit margin to 45.3%. Quarterl...
HOYA Highlights Assumptions and Risks Underpinning FY25 Q3 Outlook
Jan 30, 2026
In its FY25 third-quarter earnings presentation dated January 30, 2026, HOYA Corporation provided commentary that included forward-looking statements regarding its future plans and performance. These statements, based on management’s assumpt...
HOYA Launches ¥100 Billion Share Buyback Targeting 1.48% of Outstanding Stock
Jan 30, 2026
HOYA CORPORATION’s board has approved a share repurchase program aimed at enhancing shareholder returns, improving capital efficiency and maintaining a flexible capital policy. The company will buy back up to 5 million shares, representing a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.